Research Papers

25 of 3284 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adj…
Badiginchala R; Dattatreya PS; Suresh AVS; Nirni SS; Andra VV; Bunger D; Chaturvedi A.
Onco Targets Ther (Unknown)
Published: 2023
2/6 Transparent
Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study.
Li G; Cheng M; Hong K; Jiang Y.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction.
Buller DM; Antony M; Ristau BT.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence an…
Garciaz S; Hospital MA.
Onco Targets Ther (Unknown)
Published: 2023
2/6 Transparent
Overexpression of <i>BCL2</i>, <i>BCL6</i>, <i>VEGFR1</i> and <i>TWIST1</i> in Circulating Tumor Cells Derived from Pat…
Cerón R; Martínez A; Ramos C; De la Cruz A; García A; Mendoza I; Palmeros G; Montaño Figueroa EH; Navarrete J; Jiménez-Morales S; Martinez-Murillo C; Olarte I.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mu…
Ho MC; Chung YS; Lin YC; Hung MS; Fang YH.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Spotlight on Targeted Chemotherapy in Retinoblastoma: Safety, Efficacy, and Patient Outcomes.
Naseripour M; Mirshahi R; Kasraei H; Sedaghat A; Azimi F.
Onco Targets Ther (Unknown)
Published: 2022
2/6 Transparent
Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govit…
Fontes MS; Vargas Pivato de Almeida D; Cavalin C; Tagawa ST.
Onco Targets Ther (Unknown)
Published: 2022
2/6 Transparent
Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context.
Hoffman-Censits J; Maldonado L.
Onco Targets Ther (Unknown)
Published: 2022
2/6 Transparent
Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Oppor…
Tsang ES; Munster PN.
Onco Targets Ther (Unknown)
Published: 2022
2/6 Transparent
Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options.
Vodicka P; Klener P; Trneny M.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Licorice (<i>Glycyrrhiza glabra</i> L.)-Derived Phytochemicals Target Multiple Signaling Pathways to Confer Oncoprevent…
Tuli HS; Garg VK; Mehta JK; Kaur G; Mohapatra RK; Dhama K; Sak K; Kumar A; Varol M; Aggarwal D; Anand U; Kaur J; Gillan R; Sethi G; Bishayee A.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
7β-22 Dihydroxyhopane, Isolated from the Sub-Antarctic Lichen, Inhibits the Viability and Stemness in Glioma Stem Like …
Kim HJ; Suh SS; Park J; Shin MJ; Koo MH; Lee SJ; Jeon YJ; Lee S; Youn UJ; Kim SH.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
In vitro Characterization of Enhanced Human Immune Responses by GM-CSF Encoding HSV-1-Induced Melanoma Cells.
Delic M; Boeswald V; Goepfert K; Pabst P; Moehler M.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab.
Chiang RS; Glover MJ; Khaki AR; Srinivas S.
Onco Targets Ther (Unknown)
Published: 2022
2/6 Transparent
Spermidine Promotes Nb CAR-T Mediated Cytotoxicity to Lymphoma Cells Through Elevating Proliferation and Memory.
Wang H; Jiang D; Liu L; Zhang Y; Qin M; Qu Y; Wang L; Wu S; Zhou H; Xu T; Xu G.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advance…
Yu C; Jiang L; Yang D; Dong X; Yu R; Yu H.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Serum Levels of Galectin-9 are Increased in Cervical Cancer Patients and are Higher in Advanced Clinical Stages.
Reyes-Vallejo T; Conde-Rodríguez I; Serna-Villalobos J; Ramírez-Díaz I; Pérez-Villalobos G; Delgado-López G; Vazquez-Zamora VJ; Gutiérrez-Quiroz CT; Ávila-Jiménez L; García-Carrancá A; Martínez-Acosta L; Santos-López G; Reyes-Leyva J; Vallejo-Ruiz V.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments.
Gordon A; Johnston E; Lau DK; Starling N.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine.
Fuller RN; Kabagwira J; Vallejos PA; Folkerts AD; Wall NR.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma.
Sayegh N; Tripathi N; Agarwal N; Swami U.
Onco Targets Ther (Unknown)
Published: 2022
2/6 Transparent
Circular RNA Controls Tumor Occurrence and Development via Cell Cycle Regulation.
Liu F; Qu R; Yang L; Shi G; Hao S; Hu C.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Role of the JNK Pathway in Bladder Cancer.
Lee EH; Kim HT; Chun SY; Chung JW; Choi SH; Lee JN; Kim BS; Yoo ES; Kwon TG; Kim TH; Ha YS.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Establishment of Nomogram Model for Minimally Invasive Treatment of Small Hepatocellular Carcinoma Based on CD8<sup>+</…
Pu Q; Yu L; Wang X; Yan H; Xie Y; Du J; Yang Z.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives.
Awada A; Ahmad S; McKenzie ND; Holloway RW.
Onco Targets Ther (Unknown)
Published: 2022
3/6 Transparent
Funding Declared